Abstract 152P
Background
Adenosine accumulates in the tumor microenvironment due to abnormal tumor metabolism and hypoxia. It binds to A2A and A2B receptors on immune cells and impairs their activation and cytotoxic ability, helping cancers to evade the immune system and resist cancer therapies. Adenosine receptor antagonists that act in pathological concentrations of adenosine can rescue T cell and innate immune suppression and improve the efficacy of existing treatments.
Methods
We used structure-guided medicinal chemistry to design adenosine antagonists and measured how well they bind to A2A and A2B receptors in cells using HTRF and Tag-lite technology. Their ability to block adenosine’s effect on primary immune cells was monitored by measuring CREB phosphorylation and cytokine production. In vitro coculture assays and syngeneic mouse models were used to check the effect of immune response and tumor growth. We also used a patient-derived ex vivo tumor platform to demonstrate clinical translatability.
Results
BWC2094 is a potent A2A receptor antagonist, while BWC2562 is a potent A2A/A2B dual antagonist in a high adenosine environment. They selectively bind A2A at picomolar concentrations and had >50-fold selectivity over A1 and A3 receptors. They reduced the phosphorylation of CREB and restored the production of cytokines, such as IL2, TNFα and IFNγ in adenosine-suppressed immune cells. The lead compounds exhibited a synergistic effect with standard of care drugs in co-culture assays of tumor cells and PBMC. Both, BWC2094 and BWC2562 demonstrated good oral bioavailability in rodents (>25 %F) and dogs (>50 %F) and are well tolerated for 14 days in rat acute toxicity study. At a dose of 3mg/kg, they reduce the tumor volume as monotherapy and enhanced the anti-tumor effects of anti-PD1/PDL1 and CTLA4 in CT26, MC38, and MCA205 murine tumor models. In a patient-derived ex vivo tumor model, Precision immunotherapy using Complementary approaches in Systems Oncology (PiCaSO), they reduced tumor density, decreased Ki67 expression and increased apoptosis/necrosis.
Conclusions
BWC2094 and BWC2562 can block the immunosuppressive effects of adenosine and improve the effectiveness of existing therapies in oncology.
Legal entity responsible for the study
The authors.
Funding
Bugworks Research Inc.
Disclosure
N. Katagihallimath, R. Nandishaiah, S. Sharma, S. Venkatesan, R. Rao, N. Bharatham, M. Gupta, D. Kundu, H. Kaushik Kotakonda, R. Ramalingam Kalainesan, S. Reddy, B. Tewary, L. Maitreyi, B. Venkatraman, S. V Rekha Sody, B. Majumder: Financial Interests, Personal and Institutional, Stocks/Shares: Bugworks. S. Datta, S.Hameed: Financial Interests, Personal and Institutional, Stocks or ownership: Bugworks. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display